For the Inventor, By the Inventor

Enter inventor name

Plainsboro, NJ, United States of America

Yimin Qian

USPTO Granted Patents = 71 (Patent Applications = 49)

CIPO Patents = 5 (Patent Applications = 14)

EPO Patents = 20 (Patent Applications = 42)

Average Co-Inventor Count = 5.7

ph-index = 8

Forward Citations = 200(Granted Patents)

Forward Citations (Not Self Cited) = 159(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Wayne, NJ (US) (2006 - 2017)
Plainsboro, NJ (US) (2015 - 2024)

Company Filing History:

Arvinas Operations, Inc.

20 out of 4,945

Hoffmann-la Roche Inc.

Accutar Biotechnology Inc.

4. 7 out of 1,327

Yale University

Madrigal Pharmaceuticals, Inc.

6. 4 out of 2,405

Merck Sharp + Dohme Corp.

Tiger Biotherapeutics Inc.

Via Pharmaceuticals, Inc.

Msd R&d (china) Co., Ltd.

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Cereblon Ligands

Cyclin-Dependent Kinase Inhibitors

Androgen Receptor Degradation

Estrogen Receptor Degraders

Bromodomain-Containing Proteins

KRAS-Mutant Degrader Compounds

Enhancer Of Zeste Homolog 2

Bruton's Tyrosine Kinase Degraders

Tetrahydronaphthalene Derivatives

Indole Derivatives

Dihydropyrazolopyrimidinone Compounds

PDE2 Inhibitors

71 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12441708 - Cereblon ligands and bifunctional compounds comprising the same (2025-10-14),

2. 12338248 - Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors (2025-06-24),

3. 12312316 - Compounds and methods for the targeted degradation of androgen receptor (2025-05-27),

4. 12275716 - Modulators of estrogen receptor proteolysis and associated methods of use (2025-04-14),

5. 12264157 - Compounds and methods for the enhanced degradation of targeted proteins (2025-04-01),

6. 12239711 - Cereblon ligands and bifunctional compounds comprising the same (2025-03-04),

7. 12208095 - Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders (2025-01-28),

8. 12195459 - Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof (2025-01-14),

9. 12172981 - Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders (2024-12-24),

10. 12171831 - Compounds and methods for the targeted degradation of bromodomain- containing proteins (2024-12-24),

11. 12168058 - Glutarimide-containing KRAS-mutant degrader compounds and uses thereof (2024-12-17),

12. 12110291 - Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof (2024-10-08),

13. 11857519 - Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide (2024-01-02),

14. 11642342 - Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer (2023-05-09),

15. 11597720 - Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders (2023-03-07),

Title: Inventor Yimin Qian: Revolutionizing Technology in Plainsboro

Introduction: Yimin Qian is a visionary inventor based in Plainsboro, NJ, known for his groundbreaking contributions to the field of technology.

Latest Patents: Yimin Qian holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his innovative approach to solving complex technological challenges.

Career Highlights: With a career spanning over two decades, Yimin Qian has worked with leading tech companies, research institutions, and universities, where he has spearheaded projects that have pushed the boundaries of technological advancement.

Collaborations: Yimin Qian has collaborated with top engineers, scientists, and researchers from around the world, fostering a culture of innovation and creativity in all his projects.

Conclusion: Yimin Qian's relentless pursuit of innovation and his passion for technology continue to inspire the next generation of inventors and engineers worldwide.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…